Melanoma Beyond the Microscope in the Era of AI and Integrated Diagnostics

Abstract

Background/Objectives: Melanoma remains one of the most malignant types of skin cancer with rising incidence numbers, despite the progress made in the prevention and management of the disease. Recent technological advancements, such as developments in the field of molecular biology, imaging, and artificial intelligence (AI), have led to a paradigm shift in the diagnosis, assessment, and management of melanoma. The current review aims to integrate current research on melanoma, moving beyond the boundaries of conventional histological analysis. Methods: This is a critical appraisal narrative review that focuses on recent studies in the areas of translation research and digital health with regard to melanoma. This research particularly targeted recent studies within the last five years, with landmark studies implicated when appropriate. Evidence was synthesized within the major categories that include epidemiology, early diagnosis, histopathology, predictive biomarkers, genetic/epigenetic changes, AI-assisted diagnostic platforms, and novel therapeutic platforms & targets. Results: Early detection techniques, innovative imaging, and biomarker-guided risk adjustment can improve diagnostic accuracy and prognostic stratification. The potential of AI in dermoscopy, digital pathology, and decision analytical systems is evident, although validation, bias, and integration issues need to be addressed. Advances in immunotherapy, targeted therapies, and novel molecular/immunological targets are expanding and facilitating integrated and personalized management. Conclusions: There is a trend in melanoma research to shift towards an integrated diagnostic platform that involves the use of AI, molecular characterization, and clinical inputs to enable more accurate and personalized diagnoses. To realize this potential, there is a need to validate, collaborate, and address ethics and implementation.

1. Introduction

Cutaneous melanoma remains a highly lethal form of skin cancer with incidence numbers increasing continually over the past decades, thereby making an unequal contribution to deaths due to skin cancer on a global basis. There seems to be a rising burden of melanoma, particularly among people of fair skin, according to an increasing amount of literature on this topic, although advances in surveillance and early intervention have brought improvement in many places [1,2,3].

The traditional method for the diagnosis of melanoma involves clinical diagnosis followed by histopathological analysis of the biopsy specimen. Although the gold standard for diagnosis is the histopathological test, it is limited by the subjective variations in the test and the processing delays. More recent innovations such as dermoscopy and reflectance confocal microscopy (RCM) [4] have improved the early detection capabilities by allowing the imaging of lesion morphology in vivo and comparing them to the histopathologic characteristics of Breslow thickness and tumor-infiltrating lymphocytes [5]. The various imaging technologies mentioned above have proved to have great utility in the early detection and diagnosis of skin cancer [6].

Alongside these developments, AI innovations have also been introduced as a revolutionary approach to melanoma diagnosis (Kalidindi [7]; Alam et al. [8]; Veronesi et al. [9]). AI-assisted techniques, such as machine learning and deep learning, employing dermoscopy and histopathological image analysis, have been found to possess diagnostic efficacy equal to, and even superior to, that of human specialists, which, to a degree, reveals a promising role for AI as a supporting tool for diagnosis and research purposes. However, these developments are accompanied by fears of bias, especially in individuals with darker epidermal characteristics, as well as a paucity of multi-center studies with robust validation, which negatively impact generalizability [10].

In this regard, the purpose of this narrative review will be to offer an up-to-date and critical perspective of the literature in the field of melanoma research, shifting from traditional concepts of diagnostics to more integrated forms of diagnostics and personalized medicine. In this review, we will begin to discuss recent trends in epidemiology and prevention methods, pointing out the challenges that remain in reducing the burden of melanoma in the general population. Then, recent advances in early diagnostics and imaging methods are reviewed, before addressing histopathological aspects and novel prognostic markers. Subsequently, the genetic and epigenetic aspects of melanoma and their role in disease progression and response to therapy are analyzed. Of special importance will be the role of AI in diagnosing patients with melanoma, in terms of its potential, challenges, and ethics. Finally, recent advances in novel therapies and targets are discussed, integration of data from multimodal diagnostics, and the increasing role of digital communications and social network platforms in the realm of melanoma prevention.

Though AI is a key point in this conversation, the scope of this review is to provide a wider and more holistic point of view through the synthesis of the latest discoveries in the field of genomics, epigenetics, and advanced optical imaging. In this way, it is shown how artificial intelligence is a transformative bridge between these different areas, integrating all of these different areas into a unified point of view.

2. Epidemiology and Prevention

Melanoma is an ever-increasing important public health issue globally, being attributed to a disproportionately large number of deaths from skin cancer, although its share of incidence of skin cancer is relatively small. Using the 2020 GLOBOCAN estimates, cutaneous melanoma contributed to only 1.7% of new cancer cases globally, although incidence is steadily increasing, especially within light-skinned populations residing in developed countries. The countries that experience the highest age-standardized incidence of cutaneous melanoma include Australia, Northern and Western Europe, as well as North America [11].

Temporal studies suggest a sharp rise in melanoma cases over the past few decades. In the US alone, the incidence rates for melanoma have grown over 320 percent since the 1970s, and melanoma now appears as the fifth most common diagnosed form of cancer. More importantly, however, the death toll caused by melanoma has not been insignificant despite enhanced survival rates because of earlier detection and treatments, since melanoma still accounts for the majority of skin cancer-associated fatalities worldwide [12].

Ultraviolet (UV) radiation exposure has remained the most clearly identified and confirmed modifiable risk factor for melanoma. Both intermittent strong exposure to the sun that leads to sunburns and artificial sources of UV radiation exposure from sun beds have long been identified as major risk factors for the development of melanoma. Host factors, including fair skin phenotype, numerous nevi, family history of melanoma, immunosuppression, and genetic susceptibility, also play an important role in susceptibility [13]. Genetic variations in genes associated with pigmentation, including MC1R, have shown an association with melanoma independent of sunlight exposure, implying that gene–environment interactions exist [14]. Moreover, the finding of dysplastic or atypical nevi is known as a risk factor for a high risk of melanoma, especially in cases where several atypical lesions are found [15].

Geographic and socioeconomic influences also affect melanoma epidemiology. Incidence is higher among areas with greater environmental ultraviolet radiation and among European-descended populations, while it is lower among those with higher melanin levels. Socioeconomic factors are associated with both susceptibility to risk and preventive and early detection care; there may be greater use of screening and sun protection, but also greater participation in sun exposure, among those with higher socioeconomic groups [16].

The epidemiology of melanoma displays a wide range of variability based on geographical and population differences, influenced by a set of complex interactions of external and internal factors. In an effort to provide a clear understanding of this phenomenon,

Table 1. Epidemiologic Determinants of Melanoma.

Factor/Component	Key Point/Mechanism	Clinical Relevance	Limitations/Notes
Geography	High incidence in AU/NA/EU	Identifies high-burden regions	UV + phenotype interplay
Host phenotype	Fitzpatrick I–II, high nevus count	Stratifies individual risk	Not modifiable
Genetics	MC1R, CDKN2A variants	Familial screening subsets	Low detection in population
UV Exposure	Sunburns, tanning beds	Primary modifiable risk	Behavioral variability
Age/Sex	Younger F incidence; older M mortality	Screening + prevention targeting	Mixed bio-behavioral drivers
Prevention	Sunscreen, education, exams	↓ incidence & late-stage detection	Adherence + access gap

↓: Decrease in incidence.

has been compiled to outline the major epidemiologic factors and modifiable risk variables that affect melanoma incidence worldwide.

Strategies in preventing the disease have focused on minimizing UV exposure through public health campaigns regarding sun protection, school-based programs, and policy interventions targeting indoor tanning. Primary prevention efforts within Australia, for example, occurred at a time when rates either stabilized or decreased among younger age groups regarding melanoma incidence, indicating that public health efforts can impact trends. Despite this, there are challenges that prevention faces, including irregular enforcement of protective measures against UV rays, public compliance with sun protection practices, and controversial data about whether sunscreen protects from melanoma.

These points underscore the importance of more accurate early detection strategies, with more sophisticated screening tools and risk stratification methodologies that incorporate clinical, phenotypic, and molecular features, which are discussed within the next section.

3. Advances in Early Detection and Imaging

Early diagnosis has become an important aspect in predicting outcomes for melanoma, as there has been evidence that clearly indicates that the thickness of the melanoma detected during diagnosis has become a significant factor in predicting survival rates for patients with melanoma. In addition, as efforts continue to develop broad strategies for decreasing melanoma incidence, there have also been important improvements in early diagnostic techniques that have contributed significantly to decreasing melanoma mortality rates. Over the past several decades, there have been important improvements that continue to push the frontiers of diagnosis beyond what has been achieved with current visual diagnoses for suspicious skin lesions [17,18,19].

The prognosis in melanoma is influenced by a number of histopathologic and molecular factors, extending beyond the usual prognostic factors. Established prognostic factors for survival are Breslow thickness and ulceration, while immune biomarkers, gene expression profiles, and epigenetic modifications have been shown to have additional prognostic value.

Table 2. Diagnostic Modalities for Early Melanoma Detection.

Factor/Component	Key Point/Mechanism	Clinical Relevance	Limitations/Notes
Clinical exam	Visual triage	First-line assessment	Subjective, low specificity
Dermoscopy	Micro-pattern assessment	↑ Detection accuracy	Operator-dependent
RCM	Cellular imaging	Reduces unnecessary biopsies	Cost + limited availability
TBP	Longitudinal digital follow-up	Aids high-risk surveillance	Compliance + infrastructure
OCT	Micro-architectural imaging	Adjunct assessment	Melanoma validation limited

↑: Improvement in detection accuracy.

is a list of the major prognostic biomarkers in melanoma, and it spans histologic, immune, molecular, and epigenetic factors.

Future studies should focus on multimodal integration (dermoscopy, RCM, radiomics), the development of decision support systems for operator-independent use, prospective validation in the primary care setting, as well as health economic analyses to facilitate adoption of the system into clinical practice.

3.1. Clinical Examination and Dermoscopy

Clinical skin evaluation is still the first modality in the diagnosis of melanoma, often aided by the use of the ABCDE rule or the “ugly duckling sign”. However, it has the natural drawbacks of being subjective and dependent on the practitioner’s experience. The use of dermoscopy has significantly improved the sensitivity for the diagnosis of melanoma by allowing visualization of underlying structures that are not visible by clinical observation alone, namely the pigment network, vessels, and regression structures [20]. Several studies and meta-analyses have shown the value of dermoscopy in elevating the sensitivity for the diagnosis of melanoma compared with clinical evaluation alone when performed by experienced individuals [21].

Although the effectiveness and value of dermoscopy are well recognized, it still depends on the operator carrying out the analysis, and the accuracy of the diagnosis is greatly determined by the personal skills and knowledge of the practitioner. The fact that the level of dermoscopy diagnostic capability varies depending on the expertise and knowledge of the physician clearly indicates the need for other diagnostic tools [22].

3.2. Advanced Imaging Modal

Aside from dermoscopy, a number of advanced imaging modalities have also surfaced to improve early melanoma detection. Reflectance confocal microscopy (RCM) is a technique that presents a real-time view of the cutaneous surface at a resolution sufficient for histological analysis. RCM has been shown to possess a high degree of sensitivity and specificity for the diagnosis of melanoma and finds use particularly where lesions are uncertain and in cosmetically sensitive areas [23,24].

Total skin photography and digital dermoscopy imaging is an important part of the lifelong observation regimen for those individuals who are considered to be high-risk. This modality helps in the detection and monitoring of the skin lesions. There is evidence that suggests the use of the aforementioned modality improves the early detection of melanomas and also decreases the biopsies performed for the lesions that are not malignant [25]. Other new technologies, including multispectral imaging and optical coherence tomography, add further to this list of new, non-invasive diagnostic tests for melanoma [26].

3.3. Strengths and Limitations of Current Imaging Approaches

Collectively, these tools have increased the sensitivity of diagnosis and allowed for the early diagnosis of melanomas. Nevertheless, there exist several challenges that still need to be overcome. Most of the methods necessitate expensive, sophisticated instruments, extensive training, and significant economic costs. Furthermore, inconsistencies in interpretation, disparities in imaging methods, and unstandardized criteria for diagnosis have continued to make reproducibility difficult [27].

It is important to realize that, while the current imaging techniques do improve the evaluation of the lesions, they do not offer much in the prognosis and do not accurately represent the natural variability associated with melanomas. Thus, the diagnosis and risk estimation are mostly reliant upon the histopathologic assessment post-excisional biopsy [28].

3.4. Implications for Early Diagnosis

The developing paradigm for imaging in melanoma reflects the growing trend for more holistic diagnostic approaches, incorporating traditional assessment, sophisticated imaging technologies, and now computational analysis. Imaging for early detection has proved its benefits for the diagnosis of thinner melanomas and the subsequent outcome improvements, but its potential is hampered by the problem of standardization, accessibility, and outcomes integration [29]. Despite the advances achieved in imaging for early detection, diagnosis, and prognosis, the role of histopathologic analysis in the management and diagnosis of melanomas cannot be underestimated. This not only reflects the importance and relevance of traditional methods but also presents an opportunity for the application of innovative techniques, which will be explored in the next section.

4. Histopathology and Prognostic Biomarkers

Histopathological examination has remained the primary tool for diagnosing melanoma and has provided critical information regarding staging, prognosis, and treatment. Traditional histopathologic factors, including Breslow thickness, ulceration, mitotic rate, and lymphovascular invasion, remain the backbone for current staging systems and treatment guidelines [30,31]. Among these, Breslow thickness has been identified as the strongest independent prognostic factor and has established a strong survival association with different stages of the disease [32].

Despite the prominent position that histopathology occupies, there are several limitations in histopathological assessment. The variability in interpretation of crucial criteria, especially mitotic rate and regression, may give rise to uncertain diagnoses and risk classification [33]. Additionally, the method yields a static picture of the microscopic architecture of the tumor and does not encompass the heterogeneity and dynamic behavior of melanoma [34]. These limitations have led to an increased interest in the use of supplementary risk biomarkers that go beyond the boundaries of histopathology.

Prognosis in melanoma is influenced by a complex spectrum of histological, immune, and molecular factors that enhance prognostic accuracy beyond the American Joint Committee on Cancer (AJCC) staging system. Traditional prognostic factors, such as Breslow thickness and ulceration, remain fundamental to survival predictions, while immunologic factors, gene expression profiles, and other biologically based markers are providing new prognostic information with potential therapeutic implications.

Table 3. Prognostic Biomarkers in Melanoma.

Factor/Component	Key Point/Mechanism	Clinical Relevance	Limitations/Notes
Breslow thickness	Vertical tumor invasion depth	Strongest survival predictor	Static metric
Ulceration	Loss of epidermal continuity	Indicates aggressive disease	Interobserver variation
TIL density	Tumor immune infiltration	Predicts ICI response	No standardized scoring
GEP assays	Transcriptional risk profiling	SLN & recurrence prediction	Limited guideline adoption
5-hmC loss	Epigenetic deregulation	Marker of aggressive biology	No routine assay

presents a systematic compilation of the various factors.

The next research direction is the exploration of how multiple biomarkers can be integrated for better prognostication. This can be done by developing an integrated system that encompasses molecular information and immune-related parameters with the aim of providing better prognostication.

4.1. Tumor Microenvironment and Immune

The tumor microenvironment has recently been recognized as an important predictive factor during melanoma progression and treatment response. Tumor-infiltrating lymphocytes (TILs), which are well established as positive predictive factors, are indicative of the host immune response and are predictors of better survival in primary melanomas [35]. More recently, the importance of immune contexture, including the distribution of immune cells within the tumor microenvironment, has come into the limelight [36].

Immune-related biomarkers, such as PD-L1 expression or interferon gamma-related signature, have emerged as important elements in immunotherapy, especially for predicting the efficiency of immune checkpoint inhibitors [37]. Nonetheless, the use of different assessment approaches, along with the absence of standardized cut-off points, creates challenges in their applicability in a clinical setting, emphasizing the need for standardized assessment frameworks [38].

4.2. Molecular and Gene Expression-Based Prognostic

There have been improvements in molecular profiling, which have expanded the list of predictive biomarkers in melanomas. Gene Expression Profiling (GEP) tests have been established as predictive tools for risk of metastasis, particularly in the early stages of disease. Clinicopathologic and Gene Expression Profile (CP-GEP) models combine the predictive information of molecular profiles with conventional pathologic criteria, which help in selecting patients for sentinel Lymph Node (LN) biopsies [39,40,41].

Although these molecular aids show good prognostic accuracy, their use in practice is still controversial. Some concerns about external validity, cost-effectiveness, and usefulness in practice have restricted their use to certain settings only, and their use in practice is still not recommended universally according to any guidelines [42].

4.3. Epigenetic and Emerging

In addition to genetic modifications, another aspect that plays significant value in the induction and progression phase of melanomas is epigenetics. Disrupted DNA methylations, histone alterations, and microRNAs have been well defined in the aggressiveness and prognosis of cancer [43]. Loss of 5-hydroxymethylcytosine, for instance, was recognized as a marker for the progression of melanomas and poor prognosis, and therefore, the use of epigenetics as an additive marker in the current prediction potential has been demonstrated [44].

Nevertheless, most epigenetic biomarkers are still in research settings, and major issues in terms of assay standardization and validation would be required to be addressed in their application as clinical diagnostics [45].

4.4. Limitations of Current Prognostic

While tremendous progress has been achieved in histopathology and biomarker studies related to the risk of melanoma, no single marker can reflect the complexity of the problem. The existing prognostic methods are based only on specific variables, which does not allow them to provide valuable recommendations related to individual management [46]. In addition, the growing complexity of the histopathological and molecular information makes it difficult to implement them. All these limitations highlight the importance of the development of comprehensive diagnostic tools that are able to process multi-dimensional data. It is in this field that computational methods and AI present novel opportunities that are going to be discussed in the next part.

5. Genetic and Epigenetic Causes of Melanoma

Melanomas show high genetic and epigenetic heterogeneity, which largely explains their diverse clinical course, variable treatment response, and high resistance to interventions. Comprehensive genomic analyses have revealed the genomic profile primarily driven by mutations induced by ultraviolet radiation, classing melanomas among the most unstable human cancers with respect to their genomic integrity [47]. The genomic complexity explains treatment stratification, simultaneously creating high-dimensional data that demands ever more innovative AI tools for proper interpretation.

Genomic and epigenomic dysregulations play an essential role in the pathogenesis of melanomas and their drug sensitivity. Oncogenic mutations, BRAF, NRAS, among others, stimulate oncogenic pathways, whereas loss of function of tumor suppressors, extensive methylation, and hydroxymethylation changes affect tumor development, immune tolerance, and drug resistance.

Table 4. Genetic & Epigenetic Alterations in Melanoma.

Factor/Component	Key Point/Mechanism	Clinical Relevance	Limitations/Notes
BRAF V600E/K	MAPK pathway activation	Targeted therapy eligibility	Resistance mechanisms
NRAS Q61	MAPK/PI3K signaling	Therapeutic stratification	No direct inhibitors
CDKN2A loss	Cell cycle deregulation	Familial melanoma risk	Variable penetrance
5-hmC loss	TET dysfunction	Poor prognosis	Lab–clinic translation gap
Intratumoral heterogeneity	Multi-clonal evolution	ICI/TT resistance	Requires multi-omics

provides information on genetic and epigenetic alterations and their significance.

Future research efforts should focus on the standardization of genomic and epigenomic biomarkers and their incorporation into risk-stratification and treatment algorithms, especially in combination with immune and molecular profiling. The incorporation of genome and epigenome profiling in the paradigm of personalized oncology may hold promises for improving patient stratification, predicting therapy resistance, and designing innovative combinations in melanoma.

5.1. Key Genetic Alterations and Molecular Subtypes

Common genetic themes are responsible for the proliferation, survival, and senescence of melanoma cells. The BRAF V600 gain-of-function mutation accounts for 40% to 50% of skin-cutaneous melanoma and informs targeted therapy because of involvement in pathogenesis. NRAS and KIT mutations are hallmarks of other types with distinct pathogenesis and strategies. Loss-of-function alteration of tumor suppressors CDKN2A and TP53 are responsible for uncontrolled growth. Although these mutations are of clear biological importance, they can be obscured by the presence of co-mutations that occur simultaneously. Genome-scale sequencing analyses have also demonstrated that a given melanoma tumor can have many mutations, a point that can obscure the identification of a given pattern of mutations to a specific gene [48,49].

5.2. Epigenetic Regulation and Tumor

In addition to genetic mutations, epigenetics is an important factor in the development and progression of melanomas. It was observed in various studies that epigenetics, which is associated with gene expression, is strongly associated with the aggressiveness of the tumor, its ability to resist the immune system, and its capacity to acquire resistance to targeted therapies and immunotherapy. Additionally, reduced cellular levels of 5-hydroxymethylcytosine, which is an established epigenetics marker, contribute to the development and progression of melanoma [44].

The epigenetic plasticity allows the melanoma cells to adapt to the changing environments and pressures from therapy, which gives the cells the ability to undergo phenotypic shift. This assists in the development and outgrowth of resistant subclones. Moreover, since epigenetic plasticity assists in continuous adaptation, it becomes challenging for prognosis when using static molecular markers. There is an emerging need for techniques that would allow monitoring the evolution of cancer [50].

5.3. Genetic Heterogeneity and Clonal Evolution

Intratumoral heterogeneity is a characteristic of human melanoma, which poses a significant challenge to risk assessment and effective treatment. Analysis of single-cell/multi-region sequencing has provided evidence of the coexistence of genetically and transcriptionally distinct sub-clones within the same tumor, which may also develop due to selective pressure originating from the treatment regimen of molecular targeted therapy or immune checkpoint blockade [51].

Conventional linear models of prognosis are unable to handle such complexity since they follow single time-point sampling and inefficient incorporation of variables. On the other hand, understanding intricate molecular patterns has become increasingly dependent upon advanced computing algorithms capable of extracting latent subpatterns in multiple dimensions of biology [52], an area which has seen growing application of AI algorithms in recent years [53].

5.4. Implications for Integrated Diagnostics and AI-Based Analysis

Although molecular profiling has greatly improved the biological understanding of melanomas, the clinical application of molecular profiling faces challenges associated with the complexity of the data, the complexity of the analysis, and the lack of interpretation strategies [54]. The widespread adoption of next-generation sequencing and epigenomic profiling will result in the generation of highly dimensional datasets that are beyond the capability of conventional statistical analysis. In this respect, AI, with robust technology capable of the combination of genetic and epigenetic information as well as information derived from histopathological and imaging modalities of patients, presents a viable option to develop predictive cancer models. This assertion presents a valid a priori reason to incorporate AI tools [55,56] within the diagnosis of melanoma; hence, the discussion of AI models within the context of diagnosis shall be presented in the next section.

6. Artificial Intelligence in Melanoma Diagnosis

More recently, AI has come up as a promising diagnostic tool for melanomas, which has utilized its ability for analyzing large-scale, high-dimensional data obtained from various sources such as imaging, histopathology, and molecular studies. The inherent complexity observed in melanomas makes conventional diagnostic procedures prone to discrepancies in interpretation. The integration of advanced AI platforms has opened promising avenues for improving diagnostic accuracy and decreasing inter- and intra-observer variability in result interpretation.

The whole process of how AI works in melanoma is shown in Figure 1. The process involves data retrieval and cleaning, feature extraction, model training, and decision-making in the clinical setting. The whole process highlights how AI can integrate imaging, pathology, omics, and clinical information to provide precision oncology, predict responses, and aid in decision-making in therapy.

AI techniques find growing application in a number of related fields of melanoma, using imagery, pathologic, radiomic, genomic, and multimodal data to improve the accuracy of diagnoses, prognostication, and stratification of treatments. AI techniques used in these fields depend upon a number of computational tasks, such as classification, feature selection, clustering, and risk prediction, and demonstrate an ever-growing potential to support decision-making. Some of these AI applications can be seen in

Table 5. AI Applications Across Melanoma Domains.

Factor/Component	Key Point/Mechanism	Clinical Relevance	Limitations/Notes
Dermoscopy AI	CNN image classification	Early detection support	Dataset bias
Digital pathology AI	WSI mitotic/TIL quantification	Prognostic automation	High compute cost
Radiomics	Feature extraction + ML modeling	ICI response prediction	Standardization lacking
Genomics ML	Sequence-based clustering	Therapy selection	Tumor heterogeneity
Multimodal fusion	Image + omics + clinical	Precision oncology	Data harmonization

.

The future of artificial intelligence in melanoma will depend on having access to large, heterogeneous, and carefully annotated datasets, on the alignment of imaging and molecular modalities, and on validation in real-world settings. The combination of dermoscopic, pathological, radiomic, and genomic information in a multimodal learning model will likely improve predictive performance and guide treatment decisions, especially in the context of immunotherapy and targeted therapies. However, the future will also depend on the successful translation of artificial intelligence into an explainable model, on regulatory acceptance, and on the ease of integration into clinical practice.

6.1. AI in Clinical Imaging and Dermoscopy

Among the first uses of artificial intelligence in the field of medical diagnosis, and arguably the most publicized to date, is the examination of dermoscopic images for melanomas. Through the utilization of deep learning models, particularly those of the convolutional neural network type, the effectiveness of these models has been found to be extremely high in the detection of malignant melanomas as opposed to benign pigmented lesions on the skin. In many instances, the results of these models have been found to be on par with, or even better than, those of highly experienced dermatologists [57,58,59]. These models learn complex image patterns that might go undetected even by human observation.

Nevertheless, some challenges still exist. This is because most models are trained on selected images that might not accurately represent patients in the hospital setting, and this can impact bias and adaptability in patients with darker skin tones or types [60]. There are also discrepancies in the acquisition of images and the fact that there are no common performance targets for these models during implementation [61].

6.2. AI in Digital Pathology

The digitization of histopathological images has allowed the application of AI technology in melanoma pathology to facilitate the auto-assessment of tumor characteristics including mitotic rate, tumor-infiltrating lymphocytes, and architectural patterns [62]. AI pathology models have the potential to provide consistency in diagnostic predictions and to identify quantitative features associated with the prognosis and response to treatment.

Recent evidence has demonstrated the potential of deep learning models to predict molecule modifications and immune system-related biomarkers based on histopathological image analysis, suggesting a possible role for AI in correlating morphology with the underlying biology of tumors [63]. The incorporation of AI systems in the pathology process faces limitations due to technical hurdles, such as the cost of digitizing slides, among others [64].

6.3. Integration of AI with Molecular and Clinical Data

In addition to relying on a single modality, the most promising area for applying AI technology for melanoma has to do with its ability to combine data from more than one source. This has led to proposals for using what has come to be known as “multi-modal AI models”, which would have the ability to predict risk for the disease, as well as help with developing a course of action for treatment [65].

These holistic methods are in sync with the idea of integrated diagnostics, which involves combining various and complex information to draw inferences that can be realistically implemented. The development of effective multimodal models has been impeded by various factors, which include data fragmentation, lack of access to well-annotated data, and difficulty in encouraging interdisciplinary collaboration between clinicians, data scientists, and regulatory authorities [66].

6.4. Ethical, Regulatory, and Implementation

The implementation of AI-based systems in the medical field is accompanied by a series of challenges. Among these, the issue of transparency and interpretability is still a highly relevant and contentious topic. Such a topic becomes even more imperative when the output of the AI system has a direct effect on the treatment and diagnosis of patients [67]. The black box problem associated with deep learning models poses challenges in gaining acceptance by healthcare providers.

Validation on future subjects in multi-center clinical trials is currently restricted, and few AI systems have received broad regulatory acceptance for the diagnosis of melanoma. Overcoming these issues will involve establishing standard validation protocols, including external validation, and the implementation of AI systems into current clinical practice in such a way that complements, rather than replaces, the expertise of clinicians [68].

6.5. Future Perspectives

The future AI is expected to play an increasingly important role in caring for patients diagnosed with melanomas based on its earlier detection and treatment capabilities as well as an ability to process multidimensional data. The future of AI will place significant attention on the development of Explainable AI models as well as the development of AI models in real-world human populations while also focusing on combining AI models seamlessly with other decision-making systems. The implementation of successful AI strategies will thus require an evaluation of the ethical implications of AI.

7. AI-Guided Therapy and Personalized Medicine in Melanoma

The area of melanoma therapy has undergone a radical transformation due to the development of targeted drugs, immunomodulators, and personalized therapy. However, a large variability of responses to therapy, resistance development, and side effects is observed across different patients. This large variability of responses across different patients clearly indicates that traditional approaches of a single variable to decide therapy have certain limitations [51,69]. In this regard, artificial intelligence has appeared to be a significant enabling technology. This technology has been observed to be able to handle complex multi-parameter data and thus has been useful in precision medicine in oncology [70,71].

Targeted therapies against oncogenic drivers, especially against BRAF V600 mutations, showed substantial clinical responses, whereas the development of acquired resistance often reduces long-term efficacy [72,73]. Also, the development of immune checkpoint inhibitors against CTLA-4, PD-1, and PD-L1 has dramatically changed the melanoma therapy paradigm at all stages, though sustained clinical efficacy is only seen in some cases [74,75]. The exploration of novel immuno-oncology targets, such as LAG-3 and TIGIT, is continually leading to novel therapy opportunities, though simultaneously creating more challenges in the therapy choice [76,77]. Predictive models based on AI are possibly one approach that could efficiently address these challenges by providing an integrated analysis of genomics, epigenomics, and immune parameters for more accurate predictions [78,79].

AI contributes significantly to the design of comprehensive platforms incorporating imaging information, digital pathologies, molecular patterns, and dynamic treatment response data collected over a long-term clinical setting. ML algorithms proved effective in understanding mechanisms of treatment resistance, making predictions of treatment outcomes, and adapting treatment strategies dynamically over a period of time, including predictions by treatment response and survival rates. Compared to the conventional method of analyzing biomarkers in a non-dynamic model, AI platforms provide a dynamic and extendable model of melanoma biology and treatment response, as shown by previous studies [50,80,81].

A comparison table of the existing therapies for melanoma has also been included in

Table 6. Clinical Therapy Comparison Table.

Class	Target/ Mechanism	Indications	Clinical Benefit	Resistance Mechanisms	Notes
BRAF inhibitors (e.g., Vemurafenib, Dabrafenib)	BRAF V600E/K	BRAF+ advanced melanoma	Rapid responses	MAPK reactivation, NRAS mutations	Often combined with MEKi
MEK inhibitors (e.g., Trametinib)	MEK1/2	BRAF+ melanoma	Synergistic w/BRAFi	ERK feedback, RTK signaling	Combo standard
PD-1 inhibitors (e.g., Pembrolizumab, Nivolumab)	T-cell immune checkpoint	Advanced/ metastatic melanoma	Durable responses	T-cell exhaustion, low IFN-γ signature	First-line IO
CTLA-4 inhibitors (e.g., Ipilimumab)	T-cell activation	Metastatic melanoma	Long-term survival in subset	Immune escape	High toxicity
LAG-3/TIGIT agents (emerging)	Immune checkpoints	IO-resistant settings	Emerging clinical benefit	Unclear, immune adaptation	Under investigation

. It includes targeted therapies, immune checkpoint inhibitors, and new immuno-oncology therapies. It also mentions the targets in each therapy, when they are taken, how effective they are, and how resistance occurs. This also shows the diversity in the treatment of melanoma. The article points out the advancements that have occurred in the previous 10 years in treating melanoma, as well as the issues that exist in it.

With the progress in melanoma studies, there has been a drive for multi-parametric models for diagnosis based on AI/ML algorithms. These models are being used in various subfields, which has led to a broad and varied range of applications. This has made it more difficult to distinguish and establish the individual effects of the various modalities on the models.

In an attempt to facilitate the comprehension of these complex relationships,

Table 7. Multi-Parametric AI-Driven Integrated Diagnostics in Melanoma Beyond the Microscope.

Data Domain	Key Parameters	AI/ Computational Approach	Clinical Relevance	Main Limitations	Key Refs.
Clinical parameters	Age; sex; AJCC stage; ulceration; Lactate Dehydrogenase (LDH)	Survival ML models; Cox-based ML; gradient boosting	Risk stratification; prognosis	Retrospective bias; missing data	[30]
Dermoscopy imaging	Asymmetry; color; border; pixel-level texture	CNNs; deep learning classifiers	Early melanoma detection	Dataset imbalance; skin-type bias	[57]
Reflectance confocal microscopy	Cellular morphology; pagetoid cells; junctional nests	Pattern recognition; hybrid ML	Non-invasive diagnosis	Limited availability; operator dependence	[82]
Digital pathology	Breslow thickness; mitoses; TIL density; nuclear features	Deep CNNs; attention-based models	Prognosis; response prediction	Computational cost; regulation	[83]
Radiomics	Texture; shape; intensity features	Feature extraction + ML	Therapy response prediction	Lack of standardization	[79]
Genomics	BRAF; NRAS; NF1; TMB	Multi-omics ML integration	Targeted therapy selection	Tumor heterogeneity	[47]
Transcriptomics	Immune gene signatures; IFN-γ score	ML-based response models	Immunotherapy response	Platform variability	[84]
Epigenomics	DNA methylation; 5-hmC loss	Unsupervised ML; clustering	Prognosis; progression risk	Limited clinical validation	[44]
Tumor microenvironment	Immune cell composition; T-cell exclusion	Single-cell analysis; AI clustering	Resistance mechanisms	High complexity	[78]
Multi-modal integration	Imaging+ pathology+ omics+ clinical	Deep multimodal learning	Personalized diagnostics	Data harmonization	[85]
Longitudinal outcome modeling	Response kinetics; survival curves	Temporal ML; adaptive models	Therapy optimization	Lack of prospective trials	[51]

summarizes the main domains of data used in AI-based approaches for the diagnosis of melanoma, along with their characteristic parameters, representative computation methods, their relevance, and most important challenges in their application. In this context, not only the diversity of the types of data used in contemporary studies, but also the challenges in their application, such as imbalance, variability, complexity, and lack of standardization, come to the forefront.

The research on melanomas has now become an interdisciplinary area of research that involves the following: Population-level research on the epidemiology of melanomas; Early detection of melanomas; Histopathology and molecular studies of melanomas; Multi-omics. Though each region has been investigated thoroughly, it is crucial to evaluate all the regions together to understand how the cumulative enhancements in the melanoma care pathway work together to provide a more holistic approach to the diagnosis and treatment process. To facilitate this type of combined analysis and interpretation, the current review presents a structured and comprehensive summary of the dominant conceptual and technological domains discussed throughout the current review as provided in the table below. In particular,

Table 8. Summary of Key Concepts, Technologies, and Clinical Implications in Melanoma Research.

Domain	Key Technology	Clinical Relevance	Limitations	Refs.
Epidemiology & Prevention	UV exposure, fair skin phenotype, nevi burden	Identifies high-risk populations & informs prevention strategies	Compliance barriers, geographic variability	[11,12,13,14,15,16]
Early Detection	Dermoscopy	Improved diagnostic sensitivity vs. naked-eye exam	Operator-dependent; variability in accuracy	[20,21,22]
Early Detection	Reflectance Confocal Microscopy (RCM)	Near-histologic non-invasive imaging for equivocal lesions	Limited availability, cost, training needs	[23,24]
Surveillance	Total Body Photography & Digital Dermoscopy	Enables longitudinal mole monitoring & early melanoma detection	Requires infrastructure & patient compliance	[25]
Histopathology	Breslow Thickness	Strongest independent prognostic factor; staging utility	Static measurement; does not capture tumor heterogeneity	[30,31,32]
Immune Biomarkers	Tumor-Infiltrating Lymphocytes (TILs)	Predictive response to immunotherapy & survival	No standardized scoring system	[35,36,37]
Molecular Biomarkers	Gene Expression Profiling (GEP)	Predicts SLN metastasis and recurrence risk	Limited external validation; cost; guideline variability	[39,40,41,42]
Epigenetics	DNA methylation & 5-hmC loss	Associated with aggressiveness & poor prognosis	Clinical assays not standardized	[43,44,45]
Genetics	BRAF, NRAS, KIT mutations	Guides targeted therapy selection	Intratumoral heterogeneity & resistance	[47,48,49]
AI in Imaging	CNN-based dermoscopy classifiers	Diagnostic performance comparable to dermatologists	Dataset bias; lack of generalizability	[57,58,59,60,61,86]
AI in Pathology	Digital WSI-based feature extraction	Quantitative prognostics; mitosis/TIL detection	Digitization cost; regulatory barriers	[62,63,64]
Integrated Diagnostics	Multi-modal AI (imaging + omics + clinical)	Supports personalized therapy & risk stratification	Data harmonization, interoperability, ethics	[65,66,67,68]
Therapy & Precision Oncology	Targeted & Immune Therapies	Improved survival in BRAF+ and immunotherapy-responsive patients	Resistance, toxicity, variable response	[51,69,70,71,72,73,74,76,77]
Future Direction	Explainable & Clinically Validated AI	Enhances adoption, safety, and regulatory approval	Requires multi-center validation & bias mitigation	[85,87]

specifies: (i) the scientific or clinical domain under discussion, (ii) the important conceptual or enabling technology involved, (iii) the clinical implications and possible applications related to the enabling technology, and (iv) the important limitations or challenges which currently exist to prevent its application.

Table 9. Representative AI Platforms Supporting Drug Discovery and Precision Oncology.

Company/Platform	AI Function	Notes
Atomwise [88]	Virtual screening	CNN-based docking
Exscientia [89]	Generative drug design	First AI drug to phase I
Insilico Medicine [90]	Target ID + generative chemistry	Multi-omics + GNN
Schrödinger [91]	ML-assisted docking	Pharma integrations
Relay Therapeutics [92]	Molecular dynamics + ML	Structure-based design
DeepMind AlphaFold [93]	Protein structure prediction	Facilitates target design

illustrates some of the industry platforms that use artificial intelligence in various modules of the drug development pipeline. This highlights the growing use of AI in using computational results to make a clinically actionable strategy.

From these examples, the applications of artificial intelligence are already being implemented at various stages of the drug development pipeline. This includes but is not limited to the identification of biological targets, the virtual screening process for the identification of potential compounds, the generation of new compounds through generative techniques, and the structure-based modeling process for the understanding of interactions. The applications cited are the actual implementations of machine learning algorithms in the pharmaceutical industry.

The history of personalized medicine in the context of melanoma, therefore, is inextricably entwined with the increasing application of the principle of AI-assisted multi-modal data integration. Even with great potential, there are several hurdles associated with the application of these concepts pertaining to the validation of data interpretation, especially in the context of complex models [85,87,94].

Clinical variables, such as demographic, stage of disease, and laboratory values, form the primary basis for melanoma risk stratification. The application of AI models in these data is currently targeted primarily at predicting survival outcomes, but their effectiveness can be hampered by retrospective bias in clinical data [95].

Image analysis by dermoscopy remains a dominant approach for diagnosing melanoma. Deep learning algorithms, specifically convolutional neural networks, are effective for extracting pixel features and classifying lesions. In spite of these advances, concerns about unbalanced datasets and underrepresentation of a broad range of skin types and phenotypes remain significant [96,97].

Whole-slide imaging technology in digital pathology allows computer-assisted quantitative analysis of histopathological characteristics like nuclear morphology, mitotic rate, and tumor-infiltrating lymphocytes. AI models of pathology have shown promise in integrating prognostic information and predicting treatment response, but high computational costs and regulatory hurdles remain issues in clinical adoption of these models by healthcare providers [98].

Highly advanced non-invasive imaging methods like reflectance confocal microscopy and multispectral image analysis offer cellular detail for diagnosis [99]. AI enables better pattern recognition of these methods, but clinical applicability remains limited due to restricted availability and a lack of standard protocols for acquisition [82].

Genomic information, including oncogenic drivers and mutational burden, is an essential part of target therapy decisions and resistance prediction. AI can help combine complicated mutational and multi-omics information; yet, intratumoral heterogeneity and evolution make it difficult to apply static genomic modeling [47].

Epigenomic signatures, including DNA methylation profiles and 5-hydroxymethylcytosine depletion, also have prognostic value for melanoma. AI-powered methods for unsupervised machine learning and dimensionality reduction are very applicable for analyzing large data sets, although extensive validation for a particular diagnostic test remains difficult [100]. Immunologic markers such as immune gene expression profiles and checkpoint markers are being used more as predictors of response to immunotherapy. AI offers the ability to stratify patients and make predictions about response to treatment, but assay differences and the lack of standardized thresholds remain issues for clinical utility [84]. Finally, the strength of AI technology is revealed in multi-modal data fusion, where imaging, pathology, molecular characterization, and clinical data are combined in a unified predictive model. Personalized treatment decisions and adaptive therapy adjustment in these AI-based models, although of significant clinical value, remain hampered by issues of data integration, model interpretability, and the absence of prospective multi-center validation studies [101].

A critical change forthcoming due to the intersection of AI, multi-modal diagnostics, and personalized therapeutics represents a transformation of the melanoma treatment landscape, shifting the focus from the microscope to system-level oncology.

8. Conclusions

AI is rapidly developing into an influential area of melanoma research and has the potential to bring about a paradigm shift from the traditional assessment methods using the microscope to more holistic approaches. Additionally, the current single-parameter approaches are being replaced with more accurate and comprehensive models using AI in melanoma research as it provides an accurate understanding of the complexity of melanoma.

Throughout this review, we emphasize how AI has impacted early detection, diagnostics, prognostic stratification, and personalized therapy decisions for melanoma. Specifically, AI-assisted integration of image, histopathologic, genomic, epigenetic, and immunologic information has demonstrated promise for predicting responses, clarifying resistance mechanisms, and personalizing therapy for melanoma. Such progress supports the notion of “melanoma beyond the microscope” and suggests a future where systems approaches, rather than just providing single data points, inform decisions with implications for cancer diagnosis and therapy.

Despite these advances, there are a number of challenging problems that need to be solved to enable acceptance of AI-assistive integrative diagnostics and therapy in the mainstream clinical setting. These include the heterogeneity of the data, the lack of standardization of data acquisition and annotation, the ability to interpret the models, as well as the need for multi-center validation studies in a larger number of patients. Additionally, there are questions of bias in the models with the underrepresented dermatologic phenotypes.

Future work will concentrate on the development of transparent and interpretable AI models, ensuring such models are developed and tested on representative data to more accurately mirror the needs of the real world. This progress will depend on standardizing data practices across institutions, translating real-world data from the clinical environment, and adopting well-defined models of regulating the utilization of AI. Further, the roadmap to progress in melanoma outcomes will depend on both the advancements being made in AI technology, as well as significant collaboration across all sectors to implement AI-driven diagnoses.

In conclusion, AI has enormous potential in shaping the future of melanoma diagnosis and treatment by ensuring that more personalized modalities of oncology are pursued. Based on future advancements in technological capabilities, future approaches in the treatment of melanoma could greatly benefit from comprehensive diagnostic assistance by AI.